Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.
about
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelThe evolutionary ecology of molecular replicatorsPrevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccineAutologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysNonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies.Is an HIV vaccine possible?Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques.Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses.Repressive effect of primary virus replication on superinfection correlated with gut-derived central memory CD4(+) T cells in SHIV-infected Chinese rhesus macaquesMonkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages.Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challengeNatural Killer cell-dependent and non-dependent anti-viral activity of 2-Cys Peroxiredoxin against HIV.T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces.SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?Pathogenic infection of Rhesus macaques by an evolving SIV-HIV derived from CCR5-using envelope genes of acute HIV-1 infections.Functional effector memory T cells contribute to protection from superinfection with heterologous simian immunodeficiency virus or simian-human immunodeficiency virus isolates in Chinese rhesus macaques.High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.The role of virulence in in vivo superinfection fitness of the vertebrate RNA virus infectious hematopoietic necrosis virus.
P2860
Q27344720-33690822-7938-404F-85AD-C0D902F30428Q28595819-AFC861F9-DD7D-4A14-B3D4-18959C308B3EQ28742137-B7CF1D10-6B35-45BA-BD9F-D7F7E179F88BQ28751926-989A2FF8-0A79-43B7-98A5-AC8CA12D722CQ33877434-F0108C4B-3010-40FA-80B4-9E42B69DB6B4Q33946263-9F947643-D5DB-4C79-8D6E-8A2DC27F5AEBQ33996900-8BC06E5B-9A33-4116-A3A5-E8DCBFC64AA3Q34120102-8028E5CE-367A-45D6-A839-AD29E2BDF6B5Q34574409-BBF17C74-F40F-4154-9464-659B4500060BQ34982646-2C4F9ED8-C928-4953-9518-4B801E238B04Q34983902-3780EA73-63AB-4E24-A33D-745A58498736Q35049812-F08824EC-446E-4032-920B-197E2DBB1C7BQ35754196-F14E02BE-9BB1-48E3-8C12-E945646BA959Q35914362-35F7FD6B-8262-4254-9795-82EEE55A698CQ35985519-45D2CD00-7C68-4B5D-B13A-82DE05E372B0Q36414547-8CE6383F-9A85-4E1F-9BE9-0B450CC33704Q37032170-B8747771-B63F-4E66-8FF8-B39C0067EB5AQ37232824-BE9CEF52-7874-498A-8040-434A7A90627EQ37305694-2450CB22-4E7A-4E43-A7F0-5D24A5A52299Q37333743-265390B3-14A9-4280-A6A9-82061203C030Q37436420-0BBCF692-F77E-40FC-992C-1628DAEE68E2Q39305961-242EF637-6D32-4E07-AA1C-A31B2A7061B8Q40362873-4CFB2DAA-654E-4F2C-9AF7-AC54584D342CQ40523370-F07EE7D1-37D7-44D3-A145-D87C5F1FA0EBQ41973717-EDDA83AE-C151-48B9-AEB2-14005D015DF6
P2860
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Partial protection of Simian i ...... th a heterologous SIV isolate.
@en
Partial protection of Simian immunodeficiency virus
@nl
type
label
Partial protection of Simian i ...... th a heterologous SIV isolate.
@en
Partial protection of Simian immunodeficiency virus
@nl
prefLabel
Partial protection of Simian i ...... th a heterologous SIV isolate.
@en
Partial protection of Simian immunodeficiency virus
@nl
P2093
P2860
P356
P1433
P1476
Partial protection of Simian i ...... th a heterologous SIV isolate.
@en
P2093
Adam P Buzby
Daiva Nevidomskyte
Mohammed Asmal
Norman L Letvin
Pimkwan Jaru-Ampornpan
Srinivas S Rao
Wendy W Yeh
P2860
P304
P356
10.1128/JVI.02237-08
P407
P577
2009-01-07T00:00:00Z